| Patient | Jackie Robinson |
|---|---|
| Date of birth | 1919-01-31 |
| Identifiers | MRN HR-ML037-SYN-TD; SSN (made up) 000-37-2286 |
| Document date | 2026-11-01 |
| Author | Marcus Delacroix-Hale, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Visit for blurred vision and new floaters, chest tightness on stairs, calf pain on walking and numb feet, in a man with long-standing diabetes six weeks after the death of his son. Concerns: He is afraid of losing his sight and his independence; He wants to keep working and to stay strong for his family after his son's death. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1,000 mg oral tablet, one tablet twice daily with meals | One tablet twice daily with meals | Oral route | 1970-03-03 | active | S |
| Insulin glargine 100 units/mL pen, 30 units at bedtime, adjusted by the written plan: 2 units each week while fasting glucose is above 160 mg/dL, and 4 units less for any reading below 70 | At bedtime, by the gradual titration plan | Subcutaneous route | 1970-03-03 | active | S |
| Lisinopril 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1970-03-03 to 1971-07-29 | completed | S |
| Atorvastatin 80 mg oral tablet, one tablet daily (increased from 40 mg at intake) | One tablet daily | Oral route | 1971-07-27 | active | S |
| Aspirin 81 mg delayed-release oral tablet, one tablet daily | One tablet daily | Oral route | 1970-03-03 | active | S |
| Glucagon 3 mg nasal powder, one spray into the nose for severe low blood sugar; may repeat once after 15 minutes | As needed for severe low blood sugar | Nasal route | 1971-07-27 | active | S |
| Metoprolol succinate extended-release 25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1971-08-12 | active | S |
| Nitroglycerin 0.4 mg sublingual tablet, one under the tongue for chest pain, repeated every five minutes up to three; call 911 if pain is not better five minutes after the first | As needed for chest pain, up to three doses | Sublingual route | 1971-08-12 | active | S |
| Lisinopril 40 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating | One tablet daily, with sick-day rules | Oral route | 1971-07-29 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating, and before surgery or a colonoscopy preparation | One tablet daily, with sick-day rules | Oral route | 1971-07-29 | active | S |
| Ezetimibe 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1971-10-26 | active | S |
| Dulaglutide 0.75 mg/0.5 mL pen, one injection under the skin once a week; dose to rise to 1.5 mg after at least four weeks only if the retina remains stable | Once a week, same day each week | Subcutaneous route | 1971-10-26 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Twelve-lead electrocardiogram | 1971-07-27 to 1971-07-27 | completed | S |
| Comprehensive diabetic foot examination with a 10-g monofilament, vibration and pulses | 1971-07-27 to 1971-07-27 | completed | S |
| Dilated fundus examination of both eyes with B-scan ultrasound of the right eye, at the retina clinic | 1971-07-29 to 1971-07-29 | completed | S |
| Optical coherence tomography of the macula, both eyes | 1971-07-29 to 1971-07-29 | completed | S |
| Intravitreal injection of aflibercept 2 mg, both eyes (injection 1) | 1971-07-29 to 1971-07-29 | completed | S |
| Regadenoson myocardial perfusion stress study, at the cardiology clinic | 1971-08-12 to 1971-08-12 | completed | S |
| Wound care of the right heel blister by the clinic nurse: cleansing, non-adherent dressing and a heel offloading shoe | 1971-08-17 to 1971-08-17 | completed | S |
| Intravitreal injection of aflibercept 2 mg, both eyes (injection 2), at the retina clinic | 1971-08-26 to 1971-08-26 | completed | S |
| Advance care planning conversation, about 20 minutes | 1971-09-21 to 1971-09-21 | completed | S |
| Optical coherence tomography of the macula, both eyes, at the retina clinic | 1971-09-23 to 1971-09-23 | completed | S |
| Intravitreal injection of aflibercept 2 mg, both eyes (injection 3), at the retina clinic | 1971-09-23 to 1971-09-23 | completed | S |
| Panretinal photocoagulation, right eye (first session), at the retina clinic | 1971-10-07 to 1971-10-07 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1971-09-21 | Influenza vaccine, inactivated, this season | completed | S |
| 1971-09-21 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 1971-09-21 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
| 1971-10-26 | COVID-19 vaccine, mRNA, this season | completed | S |
| 1971-10-26 | Hepatitis B vaccine (HepB-CpG), dose 1 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| about 1957 | Diabetes diagnosed at about 37, around his retirement from baseball | D (CLM-0005) |
| by 1969 | Nerve and artery damage in both legs | D (CLM-0006) |
| 1970 | Two mild strokes | D (CLM-0007) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| brother | Two of his brothers had diabetes | D (CLM-0005) | |
| natural son | His eldest son died in an automobile accident at 24 | 24 | D (CLM-0011) |
| Concern | Status | Evidence |
|---|---|---|
| He is afraid of losing his sight and his independence | active | S |
| He wants to keep working and to stay strong for his family after his son's death | active | S |
Most recent measures: Hemoglobin A1c/Hemoglobin.total in Blood 9.2 on 1971-10-26; Glucose [Mass/volume] in Serum or Plasma 248 on 1971-07-27; Sodium [Moles/volume] in Serum or Plasma 139 on 1971-10-26; Potassium [Moles/volume] in Serum or Plasma 4.7 on 1971-10-26; Creatinine [Mass/volume] in Serum or Plasma 1.18 on 1971-10-26; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1966)/1.73 sq M 74 on 1971-10-26; Albumin/Creatinine [Mass Ratio] in Urine 54 on 1971-10-26; Cholesterol [Mass/volume] in Serum or Plasma 150 on 1971-10-26; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 74 on 1971-10-26; Cholesterol in HDL [Mass/volume] in Serum or Plasma 40 on 1971-10-26; Triglyceride [Mass/volume] in Serum or Plasma 180 on 1971-10-26; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 30 on 1971-10-26; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 24 on 1971-07-27; Hemoglobin [Mass/volume] in Blood 13.9 on 1971-07-27; Platelets [#/volume] in Blood by Automated count 250 on 1971-07-27; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 380 on 1971-07-27; Thyrotropin [Units/volume] in Serum or Plasma 1.8 on 1971-07-27; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 on 1971-10-26; Visual acuity best corrected Right eye by ETDRS eye chart 35 on 1971-07-29; Visual acuity best corrected Left eye by ETDRS eye chart 56 on 1971-07-29; Macular grid.center subfield thickness by OCT 468 on 1971-07-29; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 2 on 1971-09-21; Total score [AUDIT-C] 0 on 1971-09-21; Ankle-brachial index 0.74 on 1971-08-26 [S]
Strengths and supports: Strengths: discipline, a long habit of facing pressure in public, his faith, his work for civil rights, and a household that supports him [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Blurred vision in both eyes, worse over two months, with new floaters in the right eye for four days; acuity by Snellen chart 20/200 right and 20/80 left; undilated view poor on the right; urgent retina examination arranged | resolved | confirmed | H53.8 | S — Synthetic presenting finding, superseded by the retinal diagnosis two days later. |
| Tightness in the chest on climbing stairs for two months, easing with rest; ECG without acute change; cardiology evaluation with a stress test arranged | resolved | confirmed | R07.89 | S — Synthetic presenting finding, superseded by the coronary diagnosis after the stress test. |
| Type 2 diabetes for about fifteen years, on metformin and basal insulin, with hyperglycemia (A1c 10.4%) | active | confirmed | E11.65 | S — Synthetic modern episode linked to his documented diabetes. |
| Proliferative diabetic retinopathy in both eyes with center-involving diabetic macular edema (central subfield 412 microns right, 468 left); best-corrected acuity 35 letters right and 56 letters left | active | confirmed | E11.3513 | S — Synthetic retinal findings anchored to his documented loss of vision. |
| Vitreous hemorrhage in the right eye from proliferative retinopathy; retina attached on ultrasound | active | confirmed | H43.11 | S — Synthetic finding. |
| Hypertension with chronic kidney disease, above goal on lisinopril 20 mg (152/92 mmHg) | active | confirmed | I12.9 | S — Synthetic modern episode linked to his documented high blood pressure. |
| Diabetic kidney disease with albuminuria (urine albumin-to-creatinine ratio 86 mg/g, also raised last year) and eGFR 79 | active | confirmed | E11.22 | S — Synthetic kidney findings. |
| Chronic kidney disease G2 A2 | active | confirmed | N18.2 | S — Synthetic kidney finding. |
| Peripheral artery disease of both legs with calf pain after about one block of walking; faint foot pulses | active | confirmed | E11.51 | S — Synthetic modern episode linked to the documented artery damage in his legs. |
| Diabetic peripheral neuropathy: loss of protective sensation in both feet on monofilament testing | active | confirmed | E11.42 | S — Synthetic modern episode linked to the documented nerve damage in his legs. |
| History of two mild strokes a year ago, without lasting weakness | active | confirmed | Z86.73 | S — Synthetic modern coding of the documented strokes. |
| Hyperlipidemia: LDL 142 mg/dL on atorvastatin 40 mg, far above the goal below 55 mg/dL | active | confirmed | E78.5 | S — Synthetic laboratory finding. |
| Bereavement: his eldest son died in a car crash six weeks ago | active | confirmed | Z63.4 | S — Synthetic modern coding of a documented loss; grief is treated as grief, not as a disorder. |
| Coronary artery disease with stable angina on climbing stairs: a small reversible inferior perfusion defect on regadenoson stress imaging, ejection fraction 56%; medical therapy chosen with cardiology | active | confirmed | I25.119 | S — Synthetic coronary diagnosis anchored to his documented heart disease; no heart attack is recorded before the episode. |
| Friction blister of the right heel from new shoes, unroofed, 2.5 by 2 cm, clean base, without infection, in a neuropathic foot with peripheral artery disease | resolved | confirmed | S90.821A | S — Synthetic intercurrent problem at an unscheduled visit; it does not echo a documented event. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1971-07-27 | Hemoglobin A1c/Hemoglobin.total in Blood | 10.4 | % | Below 5.7% is normal; his first goal below 8%, then below 7%, lowered gradually | High | S |
| 1971-07-27 | Glucose [Mass/volume] in Serum or Plasma | 248 | mg/dL | 70-139 mg/dL | High | S |
| 1971-07-27 | Sodium [Moles/volume] in Serum or Plasma | 137 | mmol/L | 135-145 mmol/L | Normal | S |
| 1971-07-27 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1971-07-27 | Creatinine [Mass/volume] in Serum or Plasma | 1.12 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1971-07-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1966)/1.73 sq M | 79 | mL/min/{1.73_m2} | 90 or higher is normal; 60 to 89 is mildly decreased (G2) | Low | S |
| 1971-07-27 | Albumin/Creatinine [Mass Ratio] in Urine | 86 | mg/g | Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2) | High | S |
| 1971-07-27 | Cholesterol [Mass/volume] in Serum or Plasma | 226 | mg/dL | <=199 mg/dL | High | S |
| 1971-07-27 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 142 | mg/dL | Goal below 55 mg/dL with atherosclerotic disease | High | S |
| 1971-07-27 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 38 | mg/dL | >=40 mg/dL | Low | S |
| 1971-07-27 | Triglyceride [Mass/volume] in Serum or Plasma | 230 | mg/dL | <=149 mg/dL | High | S |
| 1971-07-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 28 | U/L | 7-55 U/L | Normal | S |
| 1971-07-27 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 8-48 U/L | Normal | S |
| 1971-07-27 | Hemoglobin [Mass/volume] in Blood | 13.9 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 1971-07-27 | Platelets [#/volume] in Blood by Automated count | 250 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1971-07-27 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 380 | pg/mL | 232-1245 pg/mL | Normal | S |
| 1971-07-27 | Thyrotropin [Units/volume] in Serum or Plasma | 1.8 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 1971-07-27 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 9 | {score} | S | ||
| 1971-07-29 | Visual acuity best corrected Right eye by ETDRS eye chart | 35 | {letters} | 85 letters is about 20/20; 35 letters is about 20/200 | Low | S |
| 1971-07-29 | Visual acuity best corrected Left eye by ETDRS eye chart | 56 | {letters} | 85 letters is about 20/20; 55 letters is about 20/80 | Low | S |
| 1971-07-29 | Macular grid.center subfield thickness by OCT | 412 | um | 200-300 um | High | S |
| 1971-07-29 | Macular grid.center subfield thickness by OCT | 468 | um | 200-300 um | High | S |
| 1971-09-21 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 2 | {score} | S | ||
| 1971-09-21 | Total score [AUDIT-C] | 0 | {score} | S | ||
| 1971-08-26 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 1971-08-26 | Potassium [Moles/volume] in Serum or Plasma | 4.8 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1971-08-26 | Creatinine [Mass/volume] in Serum or Plasma | 1.22 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1971-08-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1966)/1.73 sq M | 71 | mL/min/{1.73_m2} | 90 or higher is normal; 60 to 89 is mildly decreased (G2) | Low | S |
| 1971-08-26 | Ankle-brachial index | 0.68 | {ratio} | 1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormal | Low | S |
| 1971-08-26 | Ankle-brachial index | 0.74 | {ratio} | 1.00 to 1.40 normal; 0.91 to 0.99 borderline; 0.90 or below abnormal | Low | S |
| 1971-10-26 | Hemoglobin A1c/Hemoglobin.total in Blood | 9.2 | % | Below 5.7% is normal; his first goal below 8%, then below 7%, lowered gradually | High | S |
| 1971-10-26 | Albumin/Creatinine [Mass Ratio] in Urine | 54 | mg/g | Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2) | High | S |
| 1971-10-26 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1971-10-26 | Potassium [Moles/volume] in Serum or Plasma | 4.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1971-10-26 | Creatinine [Mass/volume] in Serum or Plasma | 1.18 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1971-10-26 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1966)/1.73 sq M | 74 | mL/min/{1.73_m2} | 90 or higher is normal; 60 to 89 is mildly decreased (G2) | Low | S |
| 1971-10-26 | Cholesterol [Mass/volume] in Serum or Plasma | 150 | mg/dL | <=199 mg/dL | Normal | S |
| 1971-10-26 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 74 | mg/dL | Goal below 55 mg/dL with atherosclerotic disease | Normal | S |
| 1971-10-26 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 40 | mg/dL | >=40 mg/dL | Normal | S |
| 1971-10-26 | Triglyceride [Mass/volume] in Serum or Plasma | 180 | mg/dL | <=149 mg/dL | High | S |
| 1971-10-26 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 7-55 U/L | Normal | S |
| 1971-10-26 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1971-07-27 | Body height | 180 | cm | S |
| 1971-07-27 | Body weight | 104 | kg | S |
| 1971-07-27 | Body mass index (BMI) [Ratio] | 32.1 | kg/m2 | S |
| 1971-07-27 | Systolic blood pressure | 152 | mm[Hg] | S |
| 1971-07-27 | Diastolic blood pressure | 92 | mm[Hg] | S |
| 1971-07-27 | Heart rate | 84 | /min | S |
| 1971-07-27 | Respiratory rate | 16 | /min | S |
| 1971-07-27 | Body temperature | 36.7 | Cel | S |
| 1971-07-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1971-07-29 | Body height | 180 | cm | S |
| 1971-07-29 | Body weight | 103.8 | kg | S |
| 1971-07-29 | Body mass index (BMI) [Ratio] | 32 | kg/m2 | S |
| 1971-07-29 | Systolic blood pressure | 148 | mm[Hg] | S |
| 1971-07-29 | Diastolic blood pressure | 90 | mm[Hg] | S |
| 1971-07-29 | Heart rate | 82 | /min | S |
| 1971-07-29 | Respiratory rate | 16 | /min | S |
| 1971-07-29 | Body temperature | 36.6 | Cel | S |
| 1971-07-29 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1971-08-17 | Body height | 180 | cm | S |
| 1971-08-17 | Body weight | 103.2 | kg | S |
| 1971-08-17 | Body mass index (BMI) [Ratio] | 31.9 | kg/m2 | S |
| 1971-08-17 | Systolic blood pressure | 136 | mm[Hg] | S |
| 1971-08-17 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 1971-08-17 | Heart rate | 64 | /min | S |
| 1971-08-17 | Respiratory rate | 16 | /min | S |
| 1971-08-17 | Body temperature | 36.7 | Cel | S |
| 1971-08-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1971-08-26 | Body height | 180 | cm | S |
| 1971-08-26 | Body weight | 102.8 | kg | S |
| 1971-08-26 | Body mass index (BMI) [Ratio] | 31.7 | kg/m2 | S |
| 1971-08-26 | Systolic blood pressure | 134 | mm[Hg] | S |
| 1971-08-26 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 1971-08-26 | Heart rate | 60 | /min | S |
| 1971-08-26 | Respiratory rate | 16 | /min | S |
| 1971-08-26 | Body temperature | 36.6 | Cel | S |
| 1971-08-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1971-09-21 | Body height | 180 | cm | S |
| 1971-09-21 | Body weight | 102.2 | kg | S |
| 1971-09-21 | Body mass index (BMI) [Ratio] | 31.5 | kg/m2 | S |
| 1971-09-21 | Systolic blood pressure | 128 | mm[Hg] | S |
| 1971-09-21 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1971-09-21 | Heart rate | 62 | /min | S |
| 1971-09-21 | Respiratory rate | 16 | /min | S |
| 1971-09-21 | Body temperature | 36.6 | Cel | S |
| 1971-09-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1971-10-26 | Body height | 180 | cm | S |
| 1971-10-26 | Body weight | 101.4 | kg | S |
| 1971-10-26 | Body mass index (BMI) [Ratio] | 31.3 | kg/m2 | S |
| 1971-10-26 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1971-10-26 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 1971-10-26 | Heart rate | 60 | /min | S |
| 1971-10-26 | Respiratory rate | 16 | /min | S |
| 1971-10-26 | Body temperature | 36.6 | Cel | S |
| 1971-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1971-07-27 | Visit for blurred vision and new floaters, chest tightness on stairs, calf pain on walking and numb feet, in a man with long-standing diabetes six weeks after the death of his son | finished | S |
| 1971-07-29 | Review after the retina consultation and first eye injections: retinal diagnosis, glucose, blood pressure and kidney medicines | finished | S |
| 1971-08-17 | Same-day sick visit for a blister on the right heel | finished | S |
| 1971-08-26 | Four weeks after the new medicines: potassium and creatinine, blood pressure, ankle-brachial index, feet, mood, and the second eye injections | finished | S |
| 1971-09-21 | Periodic adult preventive visit | finished | S |
| 1971-10-26 | Three-month review: A1c, urine albumin, lipids, eyes after laser treatment, heart, legs, grief, and a GLP-1 receptor agonist | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Urgent retina consultation within 48 hours for blurred vision with new floaters in a man with long-standing diabetes: dilated examination, OCT, and treatment of any proliferative retinopathy or macular edema; same-day attendance for a curtain over the vision or flashes | completed | GL-AAO-DR-2025, GL-ADA-RETFOOT-2026 | S |
| Glucose: continue metformin and basal insulin, titrated slowly by a written plan so that the A1c falls gradually; rescue glucagon; diabetes self-management education adapted for low vision (a talking glucose meter, an insulin pen with audible dose clicks, large-print plans) | completed | GL-ADA-GLY-2026, GL-ADA-PHARM-2026, GL-CMID-2026 | S |
| Cardiovascular risk: atorvastatin increased to 80 mg, aspirin continued, baseline ECG; cardiology evaluation of exertional chest tightness with a pharmacologic stress test, since calf pain limits walking | completed | GL-ADA-CVD-2026, GL-AHA-CCD-2023, GL-AHA-STROKE-2021, GL-CMID-2026 | S |
| Legs and feet: comprehensive foot examination today; ankle-brachial index; daily foot checks with a magnifying mirror and a bright lamp, protective shoes; podiatry | completed | GL-ADA-RETFOOT-2026, GL-ACC-PAD-2024 | S |
| Kidneys: repeat urine albumin and kidney function after any change in kidney medicines; no NSAIDs | completed | GL-ADA-CKD-2026, GL-KDIGO-CKD-2024 | S |
| Grief and mood: acknowledge the loss, PHQ-9 now and at three months, and an offer of the health center's grief counselor, which he accepted; call or text 988 if thoughts of self-harm ever arise | completed | GL-USPSTF-DEP-2023, GL-ADA-BEH-2026, GL-CMID-2026 | S |
| Coronary disease, with cardiology: metoprolol succinate 25 mg daily and nitroglycerin as needed; continue high-intensity statin and aspirin; no revascularization now for a small area of ischemia with stable symptoms; review with cardiology in three months or sooner for worse or more frequent chest pain | completed | GL-AHA-CCD-2023, GL-ADA-CVD-2026, GL-CMID-2026 | S |
| Heel blister: daily dressing by the visiting nurse three times a week and by him on other days with a large-print guide; heel offloading shoe; podiatry within two days; review weekly; a vascular surgery opinion if it is not healing within four weeks or the ankle-brachial index is very low | completed | GL-IWGDF-2023, GL-ACC-PAD-2024, GL-ADA-RETFOOT-2026 | S |
| On the retina specialist's advice: aflibercept injections in both eyes monthly for three doses, then treat-and-extend; panretinal photocoagulation to the right eye once the hemorrhage clears, and to the left if new vessels persist; vitrectomy if the hemorrhage does not clear within one to three months; low-vision evaluation; aspirin continued; glucose lowered gradually, and a GLP-1 receptor agonist only after the retina is stable, with retina review monthly | completed | GL-AAO-DR-2025, GL-ADA-RETFOOT-2026, GL-SUSTAIN6-2016 | S |
| Lisinopril increased to 40 mg and empagliflozin 10 mg started, with written sick-day rules; potassium and creatinine in four weeks; urine albumin at three months | completed | GL-ADA-CKD-2026, GL-ADA-CVD-2026, GL-KDIGO-CKD-2024, GL-CMID-2026 | S |
| Peripheral artery disease: supervised exercise therapy three times a week for twelve weeks once the heel has healed; podiatry every two to three months; vascular review if walking does not improve or any wound fails to heal | completed | GL-ACC-PAD-2024, GL-IWGDF-2023, GL-CMID-2026 | S |
| Dulaglutide 0.75 mg weekly started with the retina specialist's agreement, rising only if the retina stays stable at monthly review; ezetimibe 10 mg added; lipids four to eight weeks after the change, booked before he leaves the clinic | completed | GL-ADA-PHARM-2026, GL-ADA-CVD-2026, GL-SUSTAIN6-2016, GL-AAO-DR-2025, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Vision kept or improved: proliferative disease regressed and macular edema reduced on anti-VEGF injections and laser | 1971-10-26 | active | Hemorrhage clearing, new vessels regressing after three injections and laser to the right eye; macular thickness down in both eyes; acuity improved | S |
| A1c falling by about one point every three months without low blood sugar, to below 8% within six months and then below 7% | 1971-10-26 | active | 10.4% to 9.2% at three months; no low blood sugar | S |
| Blood pressure below 130/80 mmHg | 1971-10-26 | completed | 126/76 in the clinic | S |
| LDL cholesterol below 55 mg/dL | 1971-10-26 | active | 142 to 74 mg/dL on atorvastatin 80 mg; ezetimibe added | S |
| Walk at least three blocks without stopping, through supervised exercise | 1971-10-26 | active | From one block to two and a half blocks | S |
| Feet kept intact: daily foot checks he can do with low vision, protective footwear, and prompt care for any skin break | 1971-10-26 | active | A heel blister found early, healed in five weeks; footwear provided | S |
| Grief acknowledged and supported, with depression screening repeated | 1971-10-26 | active | Meeting the health center's grief counselor; PHQ-9 9 to 6 | S |